Frontiers in Pharmacology · Nov 16, 2026

The Effect of Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors on Diabetic Nephropathy Risk: A Real-World Evidence Study

By Kuang-Hua Huang, Min-Ling Tsai, Tung-Han Tsai et al.

Background: This study explored the association between long-term dipeptidyl peptidase-4 inhibitor (DPP-4i) use and diabetic nephropathy (DN) risk in patients with diabetes mellitus (DM) by using real-world data. Methods: Patients with new-onset DM treated with a DPP-4i or sulfonylurea between 2008 and 2017 were included. Patients who received a DPP-4i were included in the case group and divided into the following categories on the basis of the interquartile range of their cumulative defined daily dose: Q3. Propensity score matching was used to select patients who received a sulfonylurea, and these patients were assigned to the control group. After adjustment for sex, age, income level, urbanization level, comorbidities, and other antidiabetic drug use, the Cox proportional-hazards model was used to estimate the risk of DN associated with DPP-4i use over 5 years of follow-up. Result: After matching, 78,209 DPP-4i users and 156,418 sulfonylurea users were identified. Patients who received DPP-4is at Q3) were at a significantly lower DN risk compared with those who received a sulfonylurea, with an adjusted hazard ratio of 0.77 (95% confidence interval = 0.73–0.80). All DPP-4is (linagliptin, saxagliptin, sitagliptin, and vildagliptin) demonstrated a similar pattern: an increased risk of incident DN at low-to-moderate exposure levels (Q3) relative to the sulfonylurea reference group. Conclusion: All DPP-4is are associated with an increased risk of incident DN at low-to-intermediate cumulative exposure levels (Q3) compared with those who receive sulfonylureas. Despite these findings, the current evidence remains inconclusive, and additional large-scale studies are required to clarify the renal effects of DPP-4is.

The paperJournal sitePopulations

AgingResearch.News